These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28955993)

  • 21. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.
    Zhang X; Zhang X; Yu B; Hu R; Hao L
    Biochimie; 2017 Jun; 137():12-19. PubMed ID: 28223039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
    Kanouni T; Severin C; Cho RW; Yuen NY; Xu J; Shi L; Lai C; Del Rosario JR; Stansfield RK; Lawton LN; Hosfield D; O'Connell S; Kreilein MM; Tavares-Greco P; Nie Z; Kaldor SW; Veal JM; Stafford JA; Chen YK
    J Med Chem; 2020 Dec; 63(23):14522-14529. PubMed ID: 33034194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
    Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H
    Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
    Lim S; Janzer A; Becker A; Zimmer A; Schüle R; Buettner R; Kirfel J
    Carcinogenesis; 2010 Mar; 31(3):512-20. PubMed ID: 20042638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1.
    Kumarasinghe IR; Woster PM
    ACS Med Chem Lett; 2014 Jan; 5(1):29-33. PubMed ID: 24883177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.
    Tang F; Lu C; He X; Lin W; Xie B; Gao X; Peng Y; Yang D; Sun L; Weng L
    Cell Rep; 2023 Dec; 42(12):113477. PubMed ID: 37979167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
    Li Y; Tian X; Sui CG; Jiang YH; Liu YP; Meng FD
    Biomed Pharmacother; 2016 Aug; 82():498-508. PubMed ID: 27470390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles.
    Stitzlein LM; Gangadharan A; Walsh LM; Nam D; Espejo AB; Singh MM; Patel KH; Lu Y; Su X; Ezhilarasan R; Gumin J; Singh S; Sulman E; Lang FF; Chandra J
    Front Neurol; 2023; 14():1112207. PubMed ID: 37082446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
    Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
    Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
    Mandl A; Jasmine S; Krueger T; Kumar R; Coleman IM; Dalrymple SL; Antony L; Rosen DM; Jing Y; Hanratty B; Patel RA; Jin-Yih L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Speranzini V; Wang YZ; Luo J; Corey E; Sena LA; Casero RA; Lotan T; Trock BJ; Kachhap SK; Denmeade SR; Carducci MA; Mattevi A; Haffner MC; Nelson PS; Rienhoff HY; Isaacs JT; Brennen WN
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
    Schulte JH; Lim S; Schramm A; Friedrichs N; Koster J; Versteeg R; Ora I; Pajtler K; Klein-Hitpass L; Kuhfittig-Kulle S; Metzger E; Schüle R; Eggert A; Buettner R; Kirfel J
    Cancer Res; 2009 Mar; 69(5):2065-71. PubMed ID: 19223552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1).
    Sakane N; Kwon HS; Pagans S; Kaehlcke K; Mizusawa Y; Kamada M; Lassen KG; Chan J; Greene WC; Schnoelzer M; Ott M
    PLoS Pathog; 2011 Aug; 7(8):e1002184. PubMed ID: 21876670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LSD1 inhibitors for anticancer therapy: a patent review (2017-present).
    Lv YX; Tian S; Zhang ZD; Feng T; Li HQ
    Expert Opin Ther Pat; 2022 Sep; 32(9):1027-1042. PubMed ID: 35914778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer.
    Li A; Ma T; Wang S; Guo Y; Song Q; Liu H; Yu B; Feng S
    Biomed Pharmacother; 2024 Apr; 173():116240. PubMed ID: 38401512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
    Kauffman EC; Robinson BD; Downes MJ; Powell LG; Lee MM; Scherr DS; Gudas LJ; Mongan NP
    Mol Carcinog; 2011 Dec; 50(12):931-44. PubMed ID: 21400613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma.
    Leiendecker L; Jung PS; Krecioch I; Neumann T; Schleiffer A; Mechtler K; Wiesner T; Obenauf AC
    EMBO Mol Med; 2020 Nov; 12(11):e12525. PubMed ID: 33026191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
    Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
    Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.